Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with invivo efficacy. European journal of medicinal chemistry Lesniak, R. K., Nichols, R. J., Schonemann, M., Zhao, J., Gajera, C. R., Fitch, W. L., Lam, G., Nguyen, K. C., Smith, M., Montine, T. J. 1800; 229: 114080

Abstract

Mutations in the Leucine Rich Repeat Protein Kinase 2 gene (LRRK2) are the most common genetic causes of Parkinson's Disease (PD). The G2019S mutation is the most common inherited LRRK2 mutation, occurs in the kinase domain, and results in increased kinase activity. We report the discovery and development of compound 38, an indazole-based, G2019S-selective (>2000-fold vs. WT) LRRK2 inhibitor capable of entering rodent brain (Kp=0.5) and selectively inhibiting G2019S-LRRK2. The compounds disclosed herein present a starting point for further development of brain penetrant G2019S selective inhibitors that hopefully reduce lung phenotype side-effects and pave the way to providing a precision medicine for people with PD who carry the G2019S mutation.

View details for DOI 10.1016/j.ejmech.2021.114080

View details for PubMedID 34992038